+

WO2006014287A1 - Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes - Google Patents

Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes Download PDF

Info

Publication number
WO2006014287A1
WO2006014287A1 PCT/US2005/023076 US2005023076W WO2006014287A1 WO 2006014287 A1 WO2006014287 A1 WO 2006014287A1 US 2005023076 W US2005023076 W US 2005023076W WO 2006014287 A1 WO2006014287 A1 WO 2006014287A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
phe
pyridylalanine
bip
ome
Prior art date
Application number
PCT/US2005/023076
Other languages
English (en)
Other versions
WO2006014287A8 (fr
Inventor
William R. Ewing
Claudio Mapelli
Richard B. Sulsky
Tasir S. Haque
Ving G. Lee
Douglas James Riexinger
Rogelio L. Martinez
Yeheng Zhu
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006014287(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE602005020017T priority Critical patent/DE602005020017D1/de
Priority to MXPA06015193A priority patent/MXPA06015193A/es
Priority to AU2005270129A priority patent/AU2005270129A1/en
Priority to BRPI0511393-8A priority patent/BRPI0511393A/pt
Priority to JP2007520360A priority patent/JP2008505899A/ja
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to CN2005800295435A priority patent/CN101010339B/zh
Priority to EP05763871A priority patent/EP1773877B1/fr
Priority to AT05763871T priority patent/ATE461218T1/de
Priority to CA002571794A priority patent/CA2571794A1/fr
Publication of WO2006014287A1 publication Critical patent/WO2006014287A1/fr
Publication of WO2006014287A8 publication Critical patent/WO2006014287A8/fr
Priority to IL180434A priority patent/IL180434A0/en
Priority to NO20070614A priority patent/NO20070614L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • X aa6 is a naturally or nonnaturally occurring amino acid having a disubstituted alpha carbon having two side chains; wherein at least one of the two side chains has an aromatic ring and at least one of the two chains has an alkyl group; and wherein one or more carbon atoms of the amino acid is optionally substituted with one or more alkyl groups or one or more halo groups .
  • R 7 is selected from the group of hydrogen and methyl.
  • the parenteral administration may be selected from the group consisting of intravenous (IV) bolus injection, IV infusion, subcutaneous administration, intramuscular administration, intranasal administration, buccal administration, pulmonary administration and ophthalmic delivery.
  • IV intravenous
  • bolus injection IV infusion
  • subcutaneous administration intramuscular administration
  • intranasal administration buccal administration
  • pulmonary administration ophthalmic delivery.
  • PyBOP reagent benzotriazol-1-yloxy-tripyrrolidino phosphonium hexafluorophosphate
  • HBTU 2- (lH-Benzotriazol-1-yl) -1,1, 3 , 3-tetramethyluronim hexafluorophosphate
  • EDAC 3-ethyl-3 ' - (dimethylamino)propyl-carbodiimide hydrochloride (or 1- [ (3- (dimethyl)amino)propyl] ) -3- ethylcarbodiimide hydrochloride)
  • compounds of Formula IVa can be prepared by radical-induced bromination of methyl heterocycle ix (Scheme B) to give bromomethylheterocycle x.
  • Scheme B radical-induced bromination of methyl heterocycle ix
  • Alkylation of x by the method of O'Donnell as described above and similar recrystallization leads to chiral ester xiii in high enantiomeric excess.
  • Boronic acid coupling as described in Scheme A leads to compounds of Formula IVa.
  • N-sulfonamides of 11-mer peptide analogs D.
  • the synthesis of N-sulfonamides of 11-mer peptide analogs may be started from the protected 11-mer peptidyl-resin intermediate (1) (0.025 mmol) , prepared as described herein.
  • the Fmoc group is removed using the procedure described herein, and the resulting resin intermediate 2 is allowed to react with the relevant sulfonyl chloride.
  • R 3 , R 4 , Re. R 3 a. an d R ⁇ a are represented by the side chains described in Formulas Il and IVa.
  • reaction mixture was purged twice with argon and evacuated and then 43.2 mg (0.059 mmol, 0.05 equivalents) of bis (tricyclohexylphosphine) palladium (II) chloride was added and the mixture was again purged with argon and evacuated.
  • the rapidly stirred mixture was heated at 80 0 C under argon.
  • the reaction mixture was cooled to room temperature and partially concentrated to remove isopropanol.
  • the residue was partitioned between ethyl acetate and water and the aqueous phase was extracted once more with ethyl acetate. The organic extracts were combined, dried over magnesium sulfate, filtered and concentrated to give a brown oil.
  • the organic phase was washed with 0.1 M Na 2 CO 3 (2 x 20 mL) , water (1 x 20 mL) and then saturated NaCl (1 x 20 mL) .
  • the ethyl acetate was treated with 2 g of MgSO 4 and 1 g of activated charcoal for 10 minutes.
  • the solids were removed by filtration through a celite pad and the solvent removed on a rotavap. The residue began to crystallize.
  • Fresh ethyl acetate was added (10 mL) and the solution was warmed with a heat gun to redissolve the solids. The product crystallized overnight at room temperature.
  • reaction mixture was allowed to warm to room temperature. After 14h, the reaction mixture was poured into saturated sodium bicarbonate solution and extracted twice with ether. The organic extracts were combine, dried (Na 2 SO 4 ) filtered and evaporated. Purification by silica gel chromatography (5 x 15 cm column, 1:3 EtOAc/hexanes as elutant) provided the title compound as a white foam, 240 mg, 33% yield.
  • CHO-GLP-IR-19 cells (20,000 in 100 ⁇ l of media) were plated into each well of a 96-well tissue culture microtiter plate and incubated overnight in a 5% CO 2 atmosphere at 37° C.
  • PBS phosphate-buffered saline
  • a Biomek 2000 was used to serially dilute all peptides prior to beginning the assay. Serial dilutions were carried out in 100% DMSO. Peptide plates were created prior to the initiation of the assay using a Platemate Plus; 1.5 uL of compound was transferred to a V bottom plate and 150 uL of assay buffer supplemented with 100 ⁇ M 3-isobutyl-l- methylxanthine (a nonselective phosphodiesterase inhibitor) was added to the plate to give a 1:100 dilution and a 1% final concentration of DMSO.
  • PBS phosphate-buffered saline
  • a serial dilution of cAMP in the range 0.2-25.6 pmol/well was made up in lysis reagent 1 (Amersham cAMP SPA kit) . 50 ⁇ l of each cAMP standard was added by hand and 70 ⁇ l of mix reagent (Amersham cAMP SPA kit) was added using the multidrop. The plates were then sealed and counted on a Trilux counter after 15 hours. This standard curve was used to convert CPM to pmol of cAMP.
  • peptides of the present invention have EC 50 values in the range of 0.0005nM to 1OnM, more preferably in the range of 0.0005nM to 0.20OnM.
  • suitable hypolipidemic/lipid lowering agents for use in combination with the compounds of the present invention include one or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal NaVbile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants, cholesterol ester transfer protein inhibitors (e.g., CP- 529414 (Pfizer)) and/or nicotinic acid and derivatives thereof.
  • MTP inhibitors which may be employed as described above include those disclosed in U.S. Patent No. 5,595,872, U.S. Patent No.
  • HMG CoA reductase inhibitors which may be employed in combination with one or more compounds of Formula I include mevastatin and related compounds, as disclosed in U.S. Patent No. 3,983,140, lovastatin
  • Desired hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and ZD-4522.
  • bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex®, policexide®) , as well as lipostabil (Rhone-Poulenc) , Eisai E-5050 (an N-substituted ethanolamine derivative) , imanixil (HOE-402), tetrahydrolipstatin (THL) , istigmastanylphos-phorylcholine (SPC, Roche) , aminocyclodextrin (Tanabe Seiyoku) , Ajinomoto AJ-814 (azulene derivative) , melinamide (Sumitomo) , Sandoz 58- 035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives) , nicotinic acid, acipimox, acifran,
  • the hypolipidemic agent may be an upregulator of LD2 receptor activity, such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly) .
  • Suitable cholesterol absorption inhibitor for use in combination with the compounds of the invention include SCH48461 (Schering-Plough) , as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention a pour objet l’introduction de nouveaux modulateurs de récepteurs de GLP-1 (glucagon-like-peptide-1) humain dont l’activité biologique est similaire ou supérieure à celle du GLP-1 natif et qui peuvent donc être utiles pour traiter ou prévenir certains troubles et maladies associés à l’activité du GLP-1. Cette invention propose également de nouveaux peptides chimiquement modifiés qui non seulement stimulent la sécrétion d’insuline dans les cas de diabète de type II mais provoquent aussi d’autres réactions insulinotropiques bénéfiques. Ces modulateurs synthétiques de récepteurs de GLP-1 démontrent une plus grande stabilité face au clivage protéolytique ce qui en fait des outils thérapeutiques de choix pour administration par voie orale ou parentérale. Les peptides proposés en vertu de l’invention possèdent des propriétés pharmacocinétique recherchées et démontrent un potentiel avantageux selon les modèles d’efficacité pour le diabète.
PCT/US2005/023076 2004-07-02 2005-06-30 Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes WO2006014287A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002571794A CA2571794A1 (fr) 2004-07-02 2005-06-30 Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabete et de conditions connexes
EP05763871A EP1773877B1 (fr) 2004-07-02 2005-06-30 Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes
AU2005270129A AU2005270129A1 (en) 2004-07-02 2005-06-30 Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
BRPI0511393-8A BRPI0511393A (pt) 2004-07-02 2005-06-30 moduladores de peptìdeo 1 semelhantes ao glucagon humano e seu uso no tratamento de diabetes e condições relacionadas
JP2007520360A JP2008505899A (ja) 2004-07-02 2005-06-30 ヒトグルカゴン様ペプチド−１修飾因子、並びにそれの糖尿病および関連症状の治療における使用
DE602005020017T DE602005020017D1 (de) 2004-07-02 2005-06-30 Modulatoren des humanen glukagon-ähnlichen peptids 1 und ihre anwendung in der behandlung von diabetes und verwandten leiden
CN2005800295435A CN101010339B (zh) 2004-07-02 2005-06-30 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
MXPA06015193A MXPA06015193A (es) 2004-07-02 2005-06-30 Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas.
AT05763871T ATE461218T1 (de) 2004-07-02 2005-06-30 Modulatoren des humanen glukagon-ähnlichen peptids 1 und ihre anwendung in der behandlung von diabetes und verwandten leiden
IL180434A IL180434A0 (en) 2004-07-02 2006-12-28 Human glucagon - like - peptide - 1 modulators and their use in the treatment of diabetes and related conditions
NO20070614A NO20070614L (no) 2004-07-02 2007-02-01 Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav ved behandling av diabetes og beslektede tilstander.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58535804P 2004-07-02 2004-07-02
US60/585,358 2004-07-02
US68480505P 2005-05-26 2005-05-26
US60/684,805 2005-05-26

Publications (2)

Publication Number Publication Date
WO2006014287A1 true WO2006014287A1 (fr) 2006-02-09
WO2006014287A8 WO2006014287A8 (fr) 2006-05-26

Family

ID=35385064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/023076 WO2006014287A1 (fr) 2004-07-02 2005-06-30 Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes

Country Status (18)

Country Link
US (2) US7417028B2 (fr)
EP (1) EP1773877B1 (fr)
JP (1) JP2008505899A (fr)
KR (1) KR20070042162A (fr)
AR (1) AR049572A1 (fr)
AT (1) ATE461218T1 (fr)
AU (1) AU2005270129A1 (fr)
BR (1) BRPI0511393A (fr)
CA (1) CA2571794A1 (fr)
DE (1) DE602005020017D1 (fr)
ES (1) ES2340181T3 (fr)
IL (1) IL180434A0 (fr)
MX (1) MXPA06015193A (fr)
NO (1) NO20070614L (fr)
PE (1) PE20060713A1 (fr)
RU (1) RU2007104105A (fr)
TW (1) TW200611704A (fr)
WO (1) WO2006014287A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127948A2 (fr) * 2005-05-26 2006-11-30 Bristol-Myers Squibb Company Modulateurs des recepteur glp-1 a modification n-terminale
WO2007017892A2 (fr) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Nouveaux composes utilises en tant qu'agonistes de glp-i
WO2007082264A2 (fr) * 2006-01-11 2007-07-19 Bristol-Myers Squibb Company Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
WO2007139589A1 (fr) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Modulateurs des récepteurs de glp-1 à libération prolongée
WO2008062457A2 (fr) * 2006-10-03 2008-05-29 Cadila Healthcare Limited Composés antidiabétiques
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
JP2009527558A (ja) * 2006-02-22 2009-07-30 メルク エンド カムパニー インコーポレーテッド オキシントモジュリン誘導体
WO2011048614A2 (fr) 2009-10-22 2011-04-28 Cadila Healthcare Limited Antagoniste des récepteurs du glucagon et agoniste du glp-i actifs par voie orale, à base de peptidomimétiques à chaîne courte
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531788A (en) * 2001-10-18 2008-01-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
US20080044326A1 (en) * 2006-07-04 2008-02-21 Esencia Co., Ltd. Sterilizer for baby products
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2011006644A2 (fr) * 2009-07-15 2011-01-20 Lonza Ltd Procédé de production de l’exénatide et d’un analogue de l’exénatide
EP3326620B1 (fr) 2010-12-16 2020-03-04 Novo Nordisk A/S Compositions solides comportant un agoniste glp-1 et du sel de n-(8-(2-hydroxybenzoyl)amino)caprylate
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
SMT201800491T1 (it) 2012-03-22 2018-11-09 Novo Nordisk As Composizioni di peptidi glp-1 e relativa preparazione
TR201903918T4 (tr) 2012-03-22 2019-04-22 Novo Nordisk As Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
CA3039745A1 (fr) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Composition pharmaceutique, methodes de traitement et leurs utilisations
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
MA53076B1 (fr) 2018-02-02 2023-11-30 Novo Nordisk As Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
CN108409592B (zh) * 2018-05-16 2023-02-03 浙江华海药业股份有限公司 一种左乙拉西坦的杂质及其合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034332A1 (fr) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues glp-1
US20020019419A1 (en) * 2000-06-22 2002-02-14 De Laszlo Stephen E. Substituted isonipecotyl derivatives as inhibitors of cell adhesion
WO2003033671A2 (fr) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2004094461A2 (fr) * 2003-04-21 2004-11-04 Bristol-Myers Squibb Company Mimetiques du peptide 1 de type glucagon humain utilises dans le traitement du diabete et des pathologies apparentees

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (fr) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (fr) 1983-11-14 1994-03-01 William F. Hoffman Analogues oxo d'agents antihypercholesterolemiants ayant les caracteristiques de la mevinoline
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
AU599580B2 (en) 1984-12-04 1990-07-26 Sandoz Ag Indene analogs of mevalonolactone
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
HUT48208A (en) 1985-10-25 1989-05-29 Sandoz Ag Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
AU610591B2 (en) 1987-05-22 1991-05-23 E.R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5712396A (en) 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU717743B2 (en) 1995-12-13 2000-03-30 Regents Of The University Of California, The Nuclear receptor ligands and ligand binding domains
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
AU8334298A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
EP2574336A1 (fr) 1998-02-02 2013-04-03 Trustees Of Tufts College Utilisation dýinhibiteurs de dipeptidylpeptidase pour réguler le métabolisme du glucose
JP2002506075A (ja) 1998-03-09 2002-02-26 フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ セリンペプチダーゼ調節剤
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
BR9911621A (pt) 1998-07-06 2001-10-16 Bristol Myers Squibb Co Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
WO2000034331A2 (fr) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues du glp-1
EP1241158A4 (fr) 1999-12-13 2004-02-11 Chugai Pharmaceutical Co Ltd Compose a chaine laterale hydroxycarbonyl-halogenoalkyle
CN1366524A (zh) 2000-04-07 2002-08-28 三星电子株式会社 磺胺衍生物作为基质金属蛋白酶抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034332A1 (fr) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues glp-1
US20020019419A1 (en) * 2000-06-22 2002-02-14 De Laszlo Stephen E. Substituted isonipecotyl derivatives as inhibitors of cell adhesion
WO2003033671A2 (fr) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2004094461A2 (fr) * 2003-04-21 2004-11-04 Bristol-Myers Squibb Company Mimetiques du peptide 1 de type glucagon humain utilises dans le traitement du diabete et des pathologies apparentees

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
WO2007017892A2 (fr) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Nouveaux composes utilises en tant qu'agonistes de glp-i
WO2007017892A3 (fr) * 2005-05-05 2007-09-20 Cadila Healthcare Ltd Nouveaux composes utilises en tant qu'agonistes de glp-i
WO2006127948A3 (fr) * 2005-05-26 2007-04-19 Bristol Myers Squibb Co Modulateurs des recepteur glp-1 a modification n-terminale
WO2006127948A2 (fr) * 2005-05-26 2006-11-30 Bristol-Myers Squibb Company Modulateurs des recepteur glp-1 a modification n-terminale
WO2007082264A2 (fr) * 2006-01-11 2007-07-19 Bristol-Myers Squibb Company Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
WO2007082264A3 (fr) * 2006-01-11 2007-12-21 Bristol Myers Squibb Co Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
JP2009527558A (ja) * 2006-02-22 2009-07-30 メルク エンド カムパニー インコーポレーテッド オキシントモジュリン誘導体
WO2007139589A1 (fr) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Modulateurs des récepteurs de glp-1 à libération prolongée
WO2007140284A3 (fr) * 2006-05-26 2008-12-31 Bristol Myers Squibb Co Modulateurs des récepteurs de glp-1 modifiés en n-terminal
JP2009538360A (ja) * 2006-05-26 2009-11-05 ブリストル−マイヤーズ スクイブ カンパニー Ｎ末端修飾ｇｌｐ−１受容体モジュレーター
US7960349B2 (en) 2006-05-26 2011-06-14 Bristol-Myers Squibb Company N-terminally modified GLP-1 receptor modulators
WO2008062457A3 (fr) * 2006-10-03 2008-10-02 Cadila Healthcare Ltd Composés antidiabétiques
WO2008062457A2 (fr) * 2006-10-03 2008-05-29 Cadila Healthcare Limited Composés antidiabétiques
JP2010505820A (ja) * 2006-10-03 2010-02-25 カディラ・ヘルスケア・リミテッド 抗糖尿病化合物
US8841413B2 (en) 2006-10-03 2014-09-23 Cadila Healthcare Limited Antidiabetic compounds
WO2011048614A2 (fr) 2009-10-22 2011-04-28 Cadila Healthcare Limited Antagoniste des récepteurs du glucagon et agoniste du glp-i actifs par voie orale, à base de peptidomimétiques à chaîne courte
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
DE602005020017D1 (de) 2010-04-29
RU2007104105A (ru) 2008-08-10
PE20060713A1 (es) 2006-07-09
IL180434A0 (en) 2007-06-03
WO2006014287A8 (fr) 2006-05-26
NO20070614L (no) 2007-03-27
EP1773877B1 (fr) 2010-03-17
ES2340181T3 (es) 2010-05-31
US20080242593A1 (en) 2008-10-02
AU2005270129A1 (en) 2006-02-09
CA2571794A1 (fr) 2006-02-09
US7417028B2 (en) 2008-08-26
MXPA06015193A (es) 2007-02-28
KR20070042162A (ko) 2007-04-20
JP2008505899A (ja) 2008-02-28
US20060287242A1 (en) 2006-12-21
AR049572A1 (es) 2006-08-16
EP1773877A1 (fr) 2007-04-18
ATE461218T1 (de) 2010-04-15
TW200611704A (en) 2006-04-16
BRPI0511393A (pt) 2007-12-04

Similar Documents

Publication Publication Date Title
EP1773877B1 (fr) Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes
US7960349B2 (en) N-terminally modified GLP-1 receptor modulators
US20070021346A1 (en) N-terminally modified GLP-1 receptor modulators
AU2002348469B2 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7534763B2 (en) Sustained release GLP-1 receptor modulators
US7238671B2 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2002348469A1 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US20070238669A1 (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
CN101010339B (zh) 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/015193

Country of ref document: MX

Ref document number: 200610786

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2571794

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7816/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 180434

Country of ref document: IL

Ref document number: 06130105

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12007500021

Country of ref document: PH

Ref document number: 2005270129

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 552393

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2007520360

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005763871

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005270129

Country of ref document: AU

Date of ref document: 20070102

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 9841

Country of ref document: GE

Ref document number: 1020077002645

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005270129

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007104105

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580029543.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005763871

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0511393

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载